187 related articles for article (PubMed ID: 24147107)
21. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.
Cassell A; Freilino ML; Lee J; Barr S; Wang L; Panahandeh MC; Thomas SM; Grandis JR
Neoplasia; 2012 Nov; 14(11):1005-14. PubMed ID: 23226094
[TBL] [Abstract][Full Text] [Related]
22. Novel C-Terminal Heat Shock Protein 90 Inhibitors (KU711 and Ku757) Are Effective in Targeting Head and Neck Squamous Cell Carcinoma Cancer Stem cells.
Subramanian C; Kovatch KJ; Sim MW; Wang G; Prince ME; Carey TE; Davis R; Blagg BSJ; Cohen MS
Neoplasia; 2017 Dec; 19(12):1003-1011. PubMed ID: 29121598
[TBL] [Abstract][Full Text] [Related]
23. Roles of the HGF/Met signaling in head and neck squamous cell carcinoma: Focus on tumor immunity (Review).
Liu D; Zhong M; Zhan D; Zhang Y; Liu S
Oncol Rep; 2020 Dec; 44(6):2337-2344. PubMed ID: 33125120
[TBL] [Abstract][Full Text] [Related]
24. HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma.
De Herdt MJ; Baatenburg de Jong RJ
Front Biosci; 2008 Jan; 13():2516-26. PubMed ID: 17981731
[TBL] [Abstract][Full Text] [Related]
25. Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling.
Jia L; Song Q; Zhou C; Li X; Pi L; Ma X; Li H; Lu X; Shen Y
PLoS One; 2016; 11(1):e0147157. PubMed ID: 26784960
[TBL] [Abstract][Full Text] [Related]
26. Resveratrol selectively induces DNA Damage, independent of Smad4 expression, in its efficacy against human head and neck squamous cell carcinoma.
Tyagi A; Gu M; Takahata T; Frederick B; Agarwal C; Siriwardana S; Agarwal R; Sclafani RA
Clin Cancer Res; 2011 Aug; 17(16):5402-11. PubMed ID: 21705453
[TBL] [Abstract][Full Text] [Related]
27. Hepatocyte Growth Factor Receptor overexpression predicts reduced survival but its targeting is not effective in unselected HNSCC patients.
Khan M; Khaznadar SS; Routila J; Ventelä S; Schmid E; Gebhart B; Becker ET; Roider HG; Perala M; Schmitz AA; Krahn T; von Ahsen O
Head Neck; 2020 Apr; 42(4):625-635. PubMed ID: 31919967
[TBL] [Abstract][Full Text] [Related]
28. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
29. Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway.
Lau PC; Chan AT
Anticancer Drugs; 2011 Aug; 22(7):665-73. PubMed ID: 21709616
[TBL] [Abstract][Full Text] [Related]
30. Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma.
Hagege A; Saada-Bouzid E; Ambrosetti D; Rastoin O; Boyer J; He X; Rousset J; Montemagno C; Doyen J; Pedeutour F; Parola J; Bourget I; Luciano F; Bozec A; Cao Y; Pagès G; Dufies M
Cell Rep Med; 2022 Sep; 3(9):100659. PubMed ID: 36130479
[TBL] [Abstract][Full Text] [Related]
31. DKK3 Overexpression Increases the Malignant Properties of Head and Neck Squamous Cell Carcinoma Cells.
Katase N; Nishimatsu SI; Yamauchi A; Yamamura M; Terada K; Itadani M; Okada N; Hassan NMM; Nagatsuka H; Ikeda T; Nohno T; Fujita S
Oncol Res; 2018 Jan; 26(1):45-58. PubMed ID: 28470144
[TBL] [Abstract][Full Text] [Related]
32. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
33. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
34. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.
Jiang N; Wang D; Hu Z; Shin HJ; Qian G; Rahman MA; Zhang H; Amin AR; Nannapaneni S; Wang X; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Ma J; Chen ZG; Saba NF
Mol Cancer Ther; 2014 Jul; 13(7):1826-36. PubMed ID: 24748655
[TBL] [Abstract][Full Text] [Related]
35. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
[TBL] [Abstract][Full Text] [Related]
36. A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Radhakrishnan A; Nanjappa V; Raja R; Sathe G; Puttamallesh VN; Jain AP; Pinto SM; Balaji SA; Chavan S; Sahasrabuddhe NA; Mathur PP; Kumar MM; Prasad TS; Santosh V; Sukumar G; Califano JA; Rangarajan A; Sidransky D; Pandey A; Gowda H; Chatterjee A
Sci Rep; 2016 Oct; 6():36132. PubMed ID: 27796319
[TBL] [Abstract][Full Text] [Related]
37. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S
Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089
[TBL] [Abstract][Full Text] [Related]
38. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
39. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.
Prasad A; Khudaynazar N; Tantravahi RV; Gillum AM; Hoffman BS
Oncotarget; 2016 Nov; 7(48):79388-79400. PubMed ID: 27764820
[TBL] [Abstract][Full Text] [Related]
40. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
